Castle Biosciences, Inc.
CSTL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $740 | $578 | $613 | $1,078 |
| - Cash | $120 | $99 | $123 | $330 |
| + Debt | $26 | $15 | $13 | $8 |
| Enterprise Value | $647 | $495 | $504 | $756 |
| Revenue | $332 | $220 | $137 | $94 |
| % Growth | 51.1% | 60.4% | 45.7% | – |
| Gross Profit | $272 | $175 | $105 | $78 |
| % Margin | 81.9% | 79.5% | 76.6% | 83.2% |
| EBITDA | $38 | -$45 | -$58 | -$37 |
| % Margin | 11.5% | -20.5% | -42.6% | -38.9% |
| Net Income | $18 | -$57 | -$67 | -$31 |
| % Margin | 5.5% | -26.1% | -49% | -33.3% |
| EPS Diluted | 0.62 | -2.14 | -2.58 | -1.24 |
| % Growth | 129% | 17.1% | -108.1% | – |
| Operating Cash Flow | $65 | -$6 | -$42 | -$19 |
| Capital Expenditures | -$28 | -$14 | -$6 | -$3 |
| Free Cash Flow | $37 | -$19 | -$47 | -$22 |